D Thompson

Summary

Affiliation: Innovus Research Inc
Country: Canada

Publications

  1. ncbi The medical-care cost burden of obesity
    D Thompson
    Innovus Research Inc, 10 Cabot Road, Suite 102, Medford, Massachusetts 02155, USA
    Obes Rev 2:189-97. 2001
  2. ncbi Toward a pharmacoeconomic model of neuropathic pain
    David Thompson
    Innovus Research Inc, Medford, Massachusetts 02155, USA
    Clin J Pain 18:366-72. 2002
  3. ncbi The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
    Francis Creed
    School of Psychiatry and Behavioural Science, University of Manchester, England
    Gastroenterology 124:303-17. 2003
  4. ncbi Psychological responses to episodic chest pain
    Kampadi Okpa
    Salford Pain Centre, Hope Hospital, UK
    Eur J Pain 7:521-9. 2003
  5. ncbi Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    David Thompson
    Innovus Research (US) Inc, Medford, MA, USA
    Value Health 8:67-79. 2005
  6. ncbi The burden of illness associated with renal cell carcinoma in the United States
    Kathleen Lang
    i3 Innovus, Medford, MA 02155, USA
    Urol Oncol 25:368-75. 2007
  7. ncbi Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data
    Michael E Stokes
    i3 Innovus, Medford, MA, USA
    Value Health 11:213-20. 2008

Collaborators

  • S Morley
  • Francis Creed
  • Michael E Stokes
  • Kathleen Lang
  • Kampadi Okpa
  • Eric P Winer
  • Craig C Earle
  • Milton C Weinstein
  • Eduardo L Montoya
  • Kathleen Gondek
  • Brian Schwartz
  • Natalya Danchenko
  • Qasim Aziz
  • Sanchoy Sarkar
  • Anthony R Hobson
  • Teri Melaine

Detail Information

Publications7

  1. ncbi The medical-care cost burden of obesity
    D Thompson
    Innovus Research Inc, 10 Cabot Road, Suite 102, Medford, Massachusetts 02155, USA
    Obes Rev 2:189-97. 2001
    ..Despite various methodological limitations, discussed herein, this body of research leads to the inescapable conclusion that obesity exacts an immense economic toll in various countries throughout the world...
  2. ncbi Toward a pharmacoeconomic model of neuropathic pain
    David Thompson
    Innovus Research Inc, Medford, Massachusetts 02155, USA
    Clin J Pain 18:366-72. 2002
    ..The tools and techniques of this science, however, have scarcely been applied to neuropathic pain...
  3. ncbi The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
    Francis Creed
    School of Psychiatry and Behavioural Science, University of Manchester, England
    Gastroenterology 124:303-17. 2003
    ..Psychotherapy and antidepressants are effective in patients with severe irritable bowel syndrome (IBS), but the cost-effectiveness of either treatment in routine practice has not been established...
  4. ncbi Psychological responses to episodic chest pain
    Kampadi Okpa
    Salford Pain Centre, Hope Hospital, UK
    Eur J Pain 7:521-9. 2003
    ..Membership of both the three- and two-cluster profiles was not associated with membership of specific diagnostic category...
  5. ncbi Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    David Thompson
    Innovus Research (US) Inc, Medford, MA, USA
    Value Health 8:67-79. 2005
    ..As long as a desire for patient-level data from clinical trials exists, there will be a need for piggyback economic evaluations in the future...
  6. ncbi The burden of illness associated with renal cell carcinoma in the United States
    Kathleen Lang
    i3 Innovus, Medford, MA 02155, USA
    Urol Oncol 25:368-75. 2007
    ..Available treatments for localized RCC frequently lead to cure; however RCC patients with advanced disease have limited treatment options and low survival rates. Data on the economic burden of RCC are limited...
  7. ncbi Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data
    Michael E Stokes
    i3 Innovus, Medford, MA, USA
    Value Health 11:213-20. 2008
    ..Assessing the value of these treatments is compromised by a paucity of data on the impact of recurrence on economic costs and survival. The purpose of this study was to shed light on these issues...